What You Will Learn

Please join Carterra at our upcoming symposium in Boston, MA.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Workflows enhancing the speed or efficiency of biologics discovery
Emerging modalities such as next-gen antibodies: scFVs, nanobodies, bi-specifics, ADCs
AI and ML initiatives and in silico discovery programs
TPD and DEL applications
Fragment-based lead discovery and small molecule screening
Novel assay designs including HT-SPR applications
Strategies to maximize impact in specific therapeutic areas such as immuno-oncology, infectious diseases, neuroscience

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

See Agenda Below

These companies are presenting in 2026:

Agenda
9:30 – 10:00 AM	Arrive and Check-in
10:00 – 10:15 AM	Symposium Begins—Welcome
10:15 – 10:45 AM	Jon Barricelli, Senior Scientist, AstraZeneca A Few Degrees of Separation: Making Sense of SPR Kinetics Across Temperatures
	Abstract: The kinetic values measured for antibody-antigen interactions are inherently sensitive to temperature and are driven by underlying thermodynamic forces encompassed by the epitope-paratope interface. These forces are not easily predicted in large molecule-antigen complexes and, therefore, require empirical confirmation. Here, we report a detailed comparison of binding kinetics measured at both 25°C and 37°C over multiple screening campaigns and identify large changes (both increases and decreases) in association and dissociation rates. We also underscore how these changes have important consequences for candidate selection, in vivo translatability, and can impact and sometimes fundamentally alter decision-making, and project trajectories.
10:45 AM – 11:15 AM	Weijie Zhou, PhD, Senior Scientist, Merck Implementing High-Throughput Epitope Binning with Carterra for Early-Stage Biologics Hit Triage
	Abstract: We describe our implementation of Carterra’s high-throughput SPR platform, emphasizing epitope binning to accelerate early-stage biologics hit triage across multiple therapeutic areas. By integrating binning data into our discovery workflow, we rapidly classify hit diversity, prioritize complementary binding profiles, and anticipate functional behavior observed in downstream assays. Case examples show how epitope-resolved clustering helps explain divergent assay outcomes and guides selection of candidates with distinct mechanisms of action. This approach reduces downstream attrition, informs lead selection strategies, and enhances cross-program efficiency by providing actionable structural and functional insight at an early decision point.
11:15 – 11:45 AM	Nico Abuid, PhD, Field Applications Scientist, Carterra Rapid Efficient Workflows for Nearly all Sample Types from Antibodies to Fragments—Introducing the 48-Channel Carterra Vega™ SPR Platform
	Abstract: Surface plasmon resonance (SPR) has long been the gold standard for characterizing molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. With high sensitivity, high throughput biosensors, Carterra’s biosensors enable SPR screening and characterization at a new scale. The Ultra is the newest in the line of one on many biosensors, building on the one-on-many array-based architecture of Carterra’s LSA platforms which has been broadly adopted in biologics discovery, now with the sensitivity and sample handling features to enable small molecule and fragment assays. Carterra Vega™, Carterra’s newest platform, moves from the one-on-many format to a new architecture with 48 needles and 48 parallel flow cells each with two ligands and a reference. Paired with an optional plate handling robot, Vega can process up to 20,000 analyte compounds in a day against two targets. A 384-well-plate of analytes can be injected in as little as 35 minutes. This enables new approaches like dose responses in primary fragment screens and kinetic characterization of thousands of compounds a day. This talk will highlight the range and scale of assays now possible on these platforms.
11:45 – 1:00 PM	Lunch and Networking
1:00 – 1:30 PM	Rajeev Chorghade, PhD, Principal Scientist, Biophysics, GSK Biophysical Methods for Encoded Oligonucleotide Hit Qualification and Development
	Abstract: GSK applies DNA-encoded library technology to accelerate oligonucleotide discovery for challenging targets. High-throughput, rapid validation of molecular interactions remains a bottleneck. This talk explores the development of novel biophysical assays to predict downstream oligonucleotide function and liabilities. Drawing from recent case studies, these mechanistic insights are applied to triage compounds earlier in the discovery pipeline and improve confidence in hit follow-up and lead optimization.
1:30 – 2:00 PM	Networking
2:00 PM	Symposium Ends

What You Will Learn

Register Here

Agenda